WST Stock Analysis — West Pharmaceutical Services
Sector: Healthcare
AI Verdict
WST trades at a premium that only makes sense if its regulatory moat keeps delivering 20%+ earnings growth—otherwise, at 37.2x forward P/E, you're paying a steep price for safety.
Competitive Moat
West Pharmaceutical Services dominates the market for injectable drug packaging and delivery systems, supplying critical components like stoppers and seals to major pharma companies. Its moat comes from deep regulatory entrenchment and long-term customer relationships, making it hard for new entrants to disrupt supply chains for regulated drugs.
Summary
The stock is in focus as it trades at 37.2x forward earnings with analysts expecting 27.2% EPS growth next year.
Where It Stands
WST is up 60.41% over the past year, trades at 47.3x trailing P/E (well above the healthcare sector median of 22x), and its RSI of 70.0 signals overbought territory.
Key Metrics
- RSI: 70 — Near Overbought
- Trailing P/E: 47.3x
- Forward P/E: 37.2x
- PEG Ratio: 1.70
- Earnings Growth: +0.3%
- Revenue Growth: +0.1%
- Market Cap: $25.0B
- Dividend Yield: 0.00%
- 1-Year Return: 60.41%
- 52-Week High: $367.66
- 52-Week Low: $206.80
Analyst Consensus
20 Buy · 2 Hold · 0 Sell (22 analysts)
Bull Case
With forward EPS growth of 27.2% and a forward P/E of 37.2x, investors are paying up for reliable, double-digit earnings expansion in a regulated niche.
Bear Case
If the P/E reverts to the sector median of 22x, the stock could lose over 40% from current multiples, and the 70.0 RSI suggests near-term pullback risk.
Catalyst to Watch
Watch for upcoming earnings: if growth beats the 27.2% consensus, the premium may hold; any miss could trigger a sharp de-rating.